Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign Up Log In
All Resources Treatments A-Z Personal Assistant Help Center Crisis
Powered By
Real members of MyEndometrialCancerTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.

I have serous adenocarcinoma, have been in treatment for approx 2 years. Now on Keytruda and Lenvima. MRI shows new Mets to spine…

A MyEndometrialCancerTeam Member asked a question 💭
New Hudson, MI
July 28, 2025
 · 
Reactions
A MyEndometrialCancerTeam Member

I am so sorry to hear this. What treatments have you had? When did you begin the keytruda/Lenvima combo?

I began treatment for recurrent endometriod adenocarcenoma in December 2024. (Had hysterectomy in Dec 2023, had a small mass in uterus, but pathology report came back as no cancer. So no further treatment). Dec 24 began carboplatin/taxol/keytruda infusions every 6 weeks. PET at end of that showed small spots of activity where the recurrent tumor was found in Oct 2024. So I moved into radiation. Had 15 doses of external beam radiation. Pet scan 12 weeks after radiation found several new Mets (3 that were about 1inch - one at vaginal cuff, one on opposite side of pelvis from tumor, and one on the back wall of the pelvis, and half a dozen in the area of the recurrent tumor)
2 weeks later I started Lenvima.

August 25, 2025
myEndometrialCancerTeam

It must be concerning to learn about new metastases. The combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) is a recognized treatment approach for serous endometrial carcinoma, particularly when the cancer has spread. This combination therapy works by both helping your immune system fight cancer cells and Show Full Answer

It must be concerning to learn about new metastases. The combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) is a recognized treatment approach for serous endometrial carcinoma, particularly when the cancer has spread. This combination therapy works by both helping your immune system fight cancer cells and targeting the cancer directly. Serous endometrial carcinoma is known to be more aggressive than other types and can spread more quickly. When cancer spreads beyond the pelvis (stage 4), additional symptoms may develop. It's important to maintain close communication with your healthcare team about any new symptoms or concerns, as they can adjust your treatment plan as needed. Your healthcare team may consider additional treatment options to address the spinal metastases. These might include radiation therapy or other targeted treatments. Research is ongoing for new treatment combinations, so don't hesitate to ask your cancer care team about any new available treatments or clinical trials that might be appropriate for your situation.

July 28, 2025

Related Questions

View All

Correction: Cancer reoccurrence spread to chest not heart !

A MyEndometrialCancerTeam Member asked a question 💭
September 26 (edited)

Keytruda in 60 Seconds: FDA Approves Injection for Endometrial Cancer
Stage 2 Endometrial Cancer: Symptoms, Treatment Plans, and Outlook
What Is Serous Endometrial Carcinoma? 8 Facts About This Aggressive Cancer Type
Continue with Facebook
Continue with Google
By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.
Already a member? Log In